Response criteria for phase II studies of supratentorial malignant glioma.

Successful chemotherapy for recurrent malignant oligodendroglioma

Cairncross, J. G., & Macdonald, D. R. (1988) · Annals of Neurology · doi:10.1002/ana.410230408 · Cited by 345 · see citing works

Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors

Levin, V. A., Crafts, D. C., Norman, D. M., Hoffer, P. B., Spire, J., & Wilson, C. B. (1977) · Journal of neurosurgery · doi:10.3171/jns.1977.47.3.0329 · Cited by 199 · see citing works

Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significance and management.

Surbone, A., Longo, D. L., Vt, D., Ihde, D. C., Duffey, P. L., Jaffe, E. S., Solomon, D., HUBBARD, S. M., & Young, R. C. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.12.1832 · Cited by 178 · see citing works

Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response.

Warr, D. G., McKinney, S., & Tannock, I. F. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.9.1040 · Cited by 151 · see citing works

Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas

Chamberlain, M. C., Murovic, J. A., & Levin, V. A. (1988) · Neurology · doi:10.1212/wnl.38.9.1371 · Cited by 149 · see citing works

Steroid‐induced CT changes in patients with recurrent malignant glioma

Cairncross, J. G., Macdonald, D. R., Pexman, J. H. W., & Ives, F. J. (1988) · Neurology · doi:10.1212/wnl.38.5.724 · Cited by 100 · see citing works

Computerized tomography in the prognosis of malignant cerebral gliomas

Murovic, J. A., Turowski, K., Wilson, C. B., Hoshino, T., & Levin, V. A. (1986) · Journal of neurosurgery · doi:10.3171/jns.1986.65.6.0799 · Cited by 42 · see citing works

Criteria and definitions for response and relapse in children with brain tumors

Zeltzer, P. M., Friedman, H. S., Norris, D. G., & Ragab, A. H. (1985) · Cancer · doi:10.1002/1097-0142(19851001)56:7+ · Cited by 35 · see citing works

Post-Surgical Contrast Enhancement Mimicking Residual Brain Tumour

Cairncross, J. G., Pexman, J. H. W., & Rathbone, M. P. (1985) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046643 · Cited by 33 · see citing works

The accuracy of volumetric measurement of high-grade gliomas

Chisholm, R. A., Stenning, S. P., & Hawkins, T. D. (1989) · Clinical Radiology · doi:10.1016/s0009-9260(89)80007-8 · Cited by 32 · see citing works

Criteria for termination of phase II chemotherapy for patients with progressive or recurrent brain tumor

Friedman, H. S., Schold, S. C., Djang, W. T., Kurtzberg, J., Longee, D. C., Halperin, E. C., Falletta, J. M., Coleman, R. E., & Oakes, W. J. (1989) · Neurology · doi:10.1212/wnl.39.1.62 · Cited by 10 · see citing works

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works

3D Slicer as an image computing platform for the Quantitative Imaging Network

Fedorov, A., Beichel, R., Kalpathy–Cramer, J., Finet, J., Fillion‐Robin, J., Pujol, S., Bauer, C., Jennings, D. L., Fennessy, F., Milan Sonka, A., et al. (2012) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2012.05.001 · Cited by 9,095 · see citing works

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J. F., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,814 · see citing works

A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma

Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834 · see citing works

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial

Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017) · JAMA · doi:10.1001/jama.2017.18718 · Cited by 2,644 · see citing works

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

Friedman, H. S., Prados, M. D., Wen, P. Y., Mikkelsen, T., Schiff, D., Abrey, L. E., Yung, W. K. A., Paleologos, N. A., Nicholas, M. K., Jensen, R. L., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8721 · Cited by 2,463 · see citing works

Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic Oligodendrogliomas

Cairncross, J. G., Ueki, K., Zlatescu, M. C., Lisle, D. K., Finkelstein, D. M., Hammond, R. R., Silver, J. S., Stark, P. C., Macdonald, D. R., Ino, Y., et al. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.19.1473 · Cited by 1,597 · see citing works

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

Kreisl, T. N., Kim, L., Moore, K., Duic, P., Royce, C., Stroud, I., Garren, N., Mackey, M. A., Butman, J. A., Camphausen, K. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.3055 · Cited by 1,567 · see citing works

Cancer Research Communications

Calura, E., Fruscio, R., Paracchini, L., Bignotti, E., Martini, P., Sales, G., Beltrame, L., Clivio, L., Ceppi, L., Di Marino, M., et al. (2021) · doi:10.1158/1078-0432 · Cited by 1,537 · see citing works

Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme

Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Marcello, J. E., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J. H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2440 · Cited by 1,383 · see citing works

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial

Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., Taylor, L. P., Lieberman, F., Silvani, A., Fink, K. L., et al. (2015) · JAMA · doi:10.1001/jama.2015.16669 · Cited by 1,259 · see citing works

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

van den Bent, M. J., Brandes, A. A., TAPHOORN, M. J. B., Kros, J. M., Kouwenhoven, M. C. M., Delattre, J., Bernsen, H. J. J. A., Frénay, M., Tijssen, C. C., Grisold, W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2229 · Cited by 1,220 · see citing works

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

Cairncross, G. J., Wang, M., Shaw, E., Jenkins, R. B., Brachman, D. G., Buckner, J. C., Fink, K., Souhami, L., Laperrière, N., Curran, W., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.2674 · Cited by 1,152 · see citing works

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., Nikkhah, G., Papsdorf, K., Steinbach, J. P., Sabel, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70164-x · Cited by 1,136 · see citing works

Response assessment criteria for brain metastases: proposal from the RANO group

Lin, N., Lee, E. Q., Aoyama, H., Barani, I. J., Barboriak, D. P., Baumert, B. G., Bendszus, M., Brown, P. D., Camidge, D. R., Chang, S. M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70057-4 · Cited by 1,099 · see citing works

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

Vredenburgh, J. J., Desjardins, A., Herndon, J. E., Dowell, J. M., Reardon, D. A., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Wagner, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2309 · Cited by 1,078 · see citing works

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063 · see citing works

A survey of MRI-based medical image analysis for brain tumor studies

Bauer, S., Wiest, R., Nolte, L.-P., & Reyes, M. (2013) · Physics in Medicine and Biology · doi:10.1088/0031-9155/58/13/r97 · Cited by 1,036 · see citing works

Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma

Abrey, L. E., Batchelor, T. T., Ferreri, A. J. M., Gospodarowicz, M. K., Pulczynski, E. J., Zucca, E., Smith, J. R., Korfel, A., Soussain, C., DeAngelis, L. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.524 · Cited by 918 · see citing works

Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials

Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902 · see citing works

Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors

Kirson, E. D., Dbalý, V., Tovaryš, F., Vymazal, J., Soustiel, J. F., Itzhaki, A., Mordechovich, D., Steinberg-Shapira, S., Gurvich, Z., Schneiderman, R., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702916104 · Cited by 894 · see citing works

DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis

Sahm, F., Schrimpf, D., Stichel, D., Jones, D., Hielscher, T., Schefzyk, S., Okonechnikov, K., Koelsche, C., Reuß, D., Capper, D., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30155-9 · Cited by 863 · see citing works

NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

Stupp, R., Wong, E. T., Kanner, A. A., Steinberg, D., Engelhard, H., Heidecke, V., Kirson, E. D., Taillibert, S., Liebermann, F., Dbalý, V., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.04.011 · Cited by 862 · see citing works

MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

Brandes, A. A., Franceschi, E., Tosoni, A., Blatt, V., Pession, A., Tallini, G., Bertorelle, R., Bartolini, S., Calbucci, F., Andreoli, A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8163 · Cited by 841 · see citing works

Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma

Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 808 · see citing works

NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

Wick, W., Hartmann, C. J., Engel, C., Stoffels, M., Felsberg, J., Stockhammer, F., Sabel, M., Koeppen, S., Ketter, R., Meyermann, R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6497 · Cited by 803 · see citing works

Bevacizumab for recurrent malignant gliomas

Norden, A. D., Young, G. S., Setayesh, K., Muzikansky, A., Klufas, R. A., Ross, G. L., Ciampa, A. S., Ebbeling, L. G., Levy, B., Drappatz, J., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304121.57857.38 · Cited by 797 · see citing works

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

Okada, H., Weller, M., Huang, R. Y., Finocchiaro, G., Gilbert, M. R., Wick, W., Ellingson, B. M., Hashimoto, N., Pollack, I. F., Brandes, A. A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00088-1 · Cited by 788 · see citing works

Standards of care for treatment of recurrent glioblastoma—are we there yet?

Weller, M., Cloughesy, T. F., Perry, J., & Wick, W. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos273 · Cited by 766 · see citing works

Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse

Yung, W. K. A., Prados, M. D., Yayá, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R. E., Olson, J. J., Chang, S. M., O'Neill, A. M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2762 · Cited by 756 · see citing works

Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial

van den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., TAPHOORN, M. J. B., Bernsen, H. J. J. A., Frénay, M., Tijssen, C. C., Grisold, W., Sipos, L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.6078 · Cited by 745 · see citing works

Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas

Albert, N. L., Weller, M., Suchorska, B., Galldiks, N., Soffietti, R., Kim, M. M., la Fougère, C. J., Pope, W. B., Law, I. G., Arbizu, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now058 · Cited by 743 · see citing works

Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402

Cairncross, G. J., Berkey, B. A., Shaw, E., Jenkins, R. B., Scheithauer, B. W., Brachman, D. G., Buckner, J. C., Fink, K., Souhami, L., Laperierre, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3414 · Cited by 726 · see citing works

Phase I Study of DNX-2401 (Delta-24-RGD) Oncolytic Adenovirus: Replication and Immunotherapeutic Effects in Recurrent Malignant Glioma

Lang, F. F., Conrad, C. A., Gomez‐Manzano, C., Yung, W. K. A., Sawaya, R. A., Weinberg, J. S., Prabhu, S. S., Rao, G., Fuller, G. N., Aldape, K., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.8219 · Cited by 718 · see citing works

Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Galanis, E., Buckner, J. C., Maurer, M. J., Kreisberg, J. I., Ballman, K. V., Boni, J. P., Peralba, J. M., Jenkins, R. B., Dakhil, S. R., Morton, R. F., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.622 · Cited by 690 · see citing works

Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials

Ellingson, B. M., Bendszus, M., Boxerman, J. L., Barboriak, D. P., Erickson, B. J., Smits, M., Nelson, S. J., Gerstner, E. R., Alexander, B. M., Goldmacher, G., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov095 · Cited by 681 · see citing works

Diffusion Magnetic Resonance Imaging: an Early Surrogate Marker of Therapeutic Efficacy in Brain Tumors

Chenevert, T. L. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.24.2029 · Cited by 672 · see citing works

Therapy of malignant brain tumors by intratumoral implantation of retroviral vector-producing cells

Ram, Z., Culver, K. W., Oshiro, E. M., Viola, J. J., DeVroom, H. L., Otto, E., Long, Z., Chiang, Y. L., McGarrity, G. J., Muul, L. M., et al. (1997) · Nature Medicine · doi:10.1038/nm1297-1354 · Cited by 661 · see citing works

FDA Drug Approval Summary: Bevacizumab (Avastin®) as Treatment of Recurrent Glioblastoma Multiforme

Cohen, M. H., Shen, Y. L., Keegan, P., & Pazdur, R. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0121 · Cited by 651 · see citing works

The cerebrospinal fluid provides a proliferative niche for neural progenitor cells

Lehtinen, M. K., Zappaterra, M. W., Chen, X., Yang, Y. J., Hill, A. D., Lun, M., Maynard, T., Gonzalez, D., Kim, S., Ye, P., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.01.023 · Cited by 648 · see citing works

Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas

van den Bent, M. J., Wefel, J., Schiff, D., TAPHOORN, M. J. B., Jaeckle, K. A., Junck, L., Armstrong, T. S., Choucair, A. K., Waldman, A. D., Gorlia, T., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70057-2 · Cited by 641 · see citing works

Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response

Moffat, B. A., Chenevert, T. L., Lawrence, T. S., Meyer, C. R., Johnson, T. D., Dong, Q., Tsien, C. I., Mukherji, S. K., Quint, D. J., Gebarski, S. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501532102 · Cited by 639 · see citing works

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

Batchelor, T. T., Mulholland, P. J., Neyns, B., Nabors, B., Campone, M., Wick, A., Mason, W. P., Mikkelsen, T., Phuphanich, S., Ashby, L. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.2464 · Cited by 610 · see citing works

CGCG clinical practice guidelines for the management of adult diffuse gliomas

Jiang, T., Mao, Y. Q., Ma, W., Mao, Q., You, Y., Yang, X., Jiang, C., Kang, C., Li, X., Chen, L., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.024 · Cited by 605 · see citing works

Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma

Rampling, R. P., Cruickshank, G., Papanastassiou, V., Nicoll, J. A. R., Hadley, D. M., Brennan, D., Petty, R., MacLean, A. G., Harland, J., McKie, E. A., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301184 · Cited by 594 · see citing works

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clément, P. M., Frénay, M., Campone, M., Baurain, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.5984 · Cited by 574 · see citing works

Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma

da Cruz, L. C. H., Rodríguez, I., Domingues, R. C., Gasparetto, E. L., & Sorensen, A. G. (2011) · American Journal of Neuroradiology · doi:10.3174/ajnr.a2397 · Cited by 551 · see citing works

Treatment of Primary CNS Lymphoma With Methotrexate and Deferred Radiotherapy: A Report of NABTT 96–07

Batchelor, T. T., Carson, K. A., O’Neill, A., Grossman, S. A., Alavi, J. Β., New, P., Hochberg, F. H., & Priet, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.03.036 · Cited by 549 · see citing works

Combined modality therapy for primary CNS lymphoma.

DeAngelis, L. M., Yahalom, J., Thaler, H. T., & Kher, U. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.4.635 · Cited by 533 · see citing works

Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients

Ostermann, S., Csajka, C., Buclin, T., Leyvraz, S., Lejeune, F. J., Decosterd, L. A., & Stupp, R. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0807 · Cited by 521 · see citing works

Phase II Study of Cediranib, an Oral Pan–Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma

Batchelor, T. T., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Plotkin, S. R., Gerstner, E., Eichler, A. F., Drappatz, J., Hochberg, F. H., Benner, T., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3988 · Cited by 520 · see citing works

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

Wick, W., Puduvalli, V. K., Chamberlain, M. C., van den Bent, M. J., Carpentier, A. F., Cher, L., Mason, W. P., Weller, M., Hong, S., Musib, L. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2595 · Cited by 518 · see citing works

Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice

de Groot, J., Fuller, G. N., Kumar, A. J., Piao, Y., Eterovic, K. A., Ji, Y., & Conrad, C. A. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop027 · Cited by 508 · see citing works

Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous system inflammatory pathologies, a review

Weinstein, J. S., Varallyay, C. G., Dosa, E., Gahramanov, S., Hamilton, B., Rooney, W. D., Muldoon, L. L., & Neuwelt, E. A. (2010) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2009.192 · Cited by 500 · see citing works

Glioblastoma

Wirsching, H., Galanis, E., & Weller, M. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802997-8.00023-2 · Cited by 487 · see citing works

Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials

Ellingson, B. M., Wen, P. Y., & Cloughesy, T. F. (2017) · Neurotherapeutics · doi:10.1007/s13311-016-0507-6 · Cited by 481 · see citing works

Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme

Reardon, D. A., Fink, K., Mikkelsen, T., Cloughesy, T. F., O’Neill, A., Plotkin, S. R., Glantz, M., Ravin, P. D., Raizer, J. J., Rich, K. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.7510 · Cited by 478 · see citing works

Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma

Liau, L. M., Ashkan, K., Brem, S. S., Campian, J. L., Trusheim, J. E., IWAMOTO, F. M., Tran, D. D., Ansstas, G., Cobbs, C., Heth, J., et al. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.5370 · Cited by 471 · see citing works

Incidence of early pseudo‐progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

Taal, W., Brandsma, D., de Bruin, H. G., Bromberg, J. E. C., Swaak‐Kragten, A. T., Smitt, P. A. E. S., van Es, C. A., & van den Bent, M. J. (2008) · Cancer · doi:10.1002/cncr.23562 · Cited by 465 · see citing works

Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

Stupp, R., Hegi, M. E., Neyns, B., Goldbrunner, R., Schlegel, U. S., Clément, P. M., Grabenbauer, G. G., Ochsenbein, A. F., Simon, M., Dietrich, P.-Y., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.6650 · Cited by 453 · see citing works

O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate

Schoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Wagner, B. A., Cramer-Morales, K. L., Furqan, M., Sandhu, S., Carlisle, T. L., Smith, M. C., Abu Hejleh, T., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.018 · Cited by 443 · see citing works

Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.

Chen, W., Cloughesy, T. F., Kamdar, N. V., Satyamurthy, N., Bergsneider, M., Liau, L. M., Mischel, P. S., Czernin, J., Phelps, M. E., & Silverman, D. H. S. (2005) · PubMed · Cited by 437 · see citing works

Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb study

Bogdahn, U., Hau, P., Stockhammer, G., Venkataramana, N. K., Mahapatra, A. K., Suri, A., Balasubramaniam, A., Nair, S., Oliushine, V., Parfenov, V., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq142 · Cited by 433 · see citing works

Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis.

Ino, Y., Betensky, R. A., Ƶlatescu, M. C., Sasaki, H., Macdonald, D. R., Stemmer-Rachamimov, A. O., Ramsay, D. A., Cairncross, J. G., & Louis, D. N. (2001) · PubMed · Cited by 432 · see citing works

Primary Central Nervous System Lymphoma: Results of a Pilot and Phase II Study of Systemic and Intraventricular Chemotherapy With Deferred Radiotherapy

Pels, H., Schmidt‐Wolf, I. G. H., Glasmacher, A. G., Schulz, H., Engert, A., Diehl, V., Zellner, A., Schackert, G., Reichmann, H., Kroschinsky, F., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.056 · Cited by 426 · see citing works

Response Assessment in Neuro-Oncology Clinical Trials

Wen, P. Y., Chang, S. M., van den Bent, M. J., Vogelbaum, M. A., Macdonald, D. R., & Lee, E. Q. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.7511 · Cited by 426 · see citing works

Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08

Wen, P. Y., Yung, W. K. A., Lamborn, K. R., Dahia, P. L. M., Wang, Y., Peng, B., Abrey, L. E., Raizer, J. J., Cloughesy, T. F., Fink, K., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0773 · Cited by 424 · see citing works

A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

Schuster, J. M., Lai, R. K., Recht, L. D., Reardon, D. A., Paleologos, N. A., Groves, M. D., Mrugała, M. M., Jensen, R. L., Baehring, J. M., Sloan, A. E., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou348 · Cited by 422 · see citing works

Phase II Trial of the Antiangiogenic Agent Thalidomide in Patients With Recurrent High-Grade Gliomas

Fine, H. A., Figg, W. D., Jaeckle, K. A., Wen, P. Y., Kyritsis, A. P., Loeffler, J. S., Levin, V. A., Black, P. M., Kaplan, R. S., Pluda, J. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.708 · Cited by 419 · see citing works

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

Lamborn, K. R., Yung, W. K. A., Chang, S. M., Wen, P. Y., Cloughesy, T. F., DeAngelis, L. M., Robins, H. I., Lieberman, F. S., Fine, H. A., Fink, K., et al. (2008) · Neuro-Oncology · doi:10.1215/15228517-2007-062 · Cited by 417 · see citing works

Phase I/II Trial of Intravenous NDV-HUJ Oncolytic Virus in Recurrent Glioblastoma Multiforme

Freeman, A. I., Zakay‐Rones, Z., Gomori, J. M., Linetsky, E., Rasooly, L., Greenbaum, E., Rozenman-Yair, S., Panet, A., Libson, E., Irving, C. S., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.08.016 · Cited by 407 · see citing works

Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review

Kubben, P., ter Meulen, K. J., Schijns, O. E. M. G., ter Laak-Poort, M., van Overbeeke, J. J., & van Santbrink, H. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70130-9 · Cited by 407 · see citing works

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

Chang, S. M., Wen, P. Y., Cloughesy, T. F., Greenberg, H. S., Schiff, D., Conrad, C. A., Fink, K., Robins, H. I., DeAngelis, L. M., Raizer, J. J., et al. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-1444-0 · Cited by 396 · see citing works

Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study

Chen, W., Delaloye, S., Silverman, D. H. S., Geist, C. L., Czernin, J. G., Sayre, J. W., Satyamurthy, N., Pope, W. B., Lai, A., Phelps, M. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5825 · Cited by 391 · see citing works

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

van den Bent, M. J., Baumert, B. G., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., Clément, P. M., Baurain, J. F., Mason, W. P., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31442-3 · Cited by 389 · see citing works

Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status

Brandes, A. A., Tosoni, A., Franceschi, E., Sotti, G., Frezza, G., Amistà, P., Morandi, L., Spagnolli, F., & Ermani, M. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4969 · Cited by 383 · see citing works

RECIST 1.1 – Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group

Schwartz, L. H., Seymour, L., Litière, S., Ford, R., Gwyther, S. J., Mandrekar, S. J., Shankar, L. K., Bogaerts, J., Chen, A. P., Dancey, J. E., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.082 · Cited by 383 · see citing works

Tumor-Treating Fields: A Fourth Modality in Cancer Treatment

Mun, E. J., Babiker, H. M., Weinberg, U., Kirson, E. D., & Von Hoff, D. D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1117 · Cited by 380 · see citing works

Pseudoprogression and pseudoresponse in the treatment of gliomas

Brandsma, D., & van den Bent, M. J. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328332363e · Cited by 376 · see citing works

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P.-Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., et al. (2001) · Annals of Oncology · doi:10.1023/a:1008382516636 · Cited by 372 · see citing works

Changing Paradigms—An Update on the Multidisciplinary Management of Malignant Glioma

Stupp, R., Hegi, M. E., van den Bent, M. J., Mason, W. P., Weller, M., Mirimanoff, R. O., & Cairncross, J. G. (2006) · The Oncologist · doi:10.1634/theoncologist.11-2-165 · Cited by 372 · see citing works

Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas

Gutin, P. H., IWAMOTO, F. M., Beal, K. P., Mohile, N. A., Karimi, S., Hou, B. L., Lymberis, S. C., Yamada, Y. J., Chang, J., & Abrey, L. E. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.10.043 · Cited by 369 · see citing works

Advanced MRI and PET imaging for assessment of treatment response in patients with gliomas

Dhermain, F. G., Hau, P., Lanfermann, H., Jacobs, A. H., & van den Bent, M. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70181-2 · Cited by 367 · see citing works

Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma

Sampson, J. H., Aldape, K., Archer, G. E., Coan, A., Desjardins, A., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq157 · Cited by 366 · see citing works

Corticosteroids in brain cancer patients: benefits and pitfalls

Dietrich, J., Rao, K., Pastorino, S., & Kesari, S. (2011) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.11.1 · Cited by 362 · see citing works

Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

Galanis, E., Jaeckle, K. A., Maurer, M. J., Reid, J. M., Ames, M. M., Hardwick, J. S., Reilly, J. F., Loboda, A. P., Nebozhyn, M., Fantin, V. R., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.0694 · Cited by 360 · see citing works

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression

de Wit, M. Y., de Bruin, H. G., Eijkenboom, W. M. H., Smitt, P. A. E. S., & van den Bent, M. J. (2004) · Neurology · doi:10.1212/01.wnl.0000133398.11870.9a · Cited by 356 · see citing works

Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma

Friedman, H. S., Petros, W. P., Friedman, A. H., Schaaf, L. J., Kerby, T., Lawyer, J., Parry, M., Houghton, P. J., Lovell, S., Rasheed, K., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1516 · Cited by 355 · see citing works

Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme

D, R. P. M., Ricci‐Vitiani, L., Banna, G. L., Signore, M., Lombardi, D., Todaro, M., Stassi, G., Martini, M., Maira, G., Larocca, L. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0644 · Cited by 354 · see citing works

Multifunctional nanoparticles for brain tumor imaging and therapy

Cheng, Y., Morshed, R. A., Auffinger, B., Tobias, A. L., & Lesniak, M. S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.006 · Cited by 351 · see citing works

Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies

Verma, N., Cowperthwaite, M. C., Burnett, M. G., & Markey, M. K. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos307 · Cited by 351 · see citing works

“Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer

Grommes, C., Oxnard, G. R., Kris, M. G., Miller, V. A., Pao, W., Holodny, A. I., Clarke, J. L., & Lassman, A. B. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor121 · Cited by 349 · see citing works

High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Stupp, R., Tonn, J., Brada, M., & Pentheroudakis, G. E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq187 · Cited by 348 · see citing works

Perfusion MRI: The Five Most Frequently Asked Clinical Questions

Essig, M., Nguyen, T., Shiroishi, M. S., Saake, M., Provenzale, J. M., Enterline, D. S., Anzalone, N., Dörfler, A., Rovira, À., Wintermark, M., et al. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.12.9544 · Cited by 346 · see citing works

Hypofractionated Stereotactic Radiation Therapy: An Effective Therapy for Recurrent High-Grade Gliomas

Fogh, S. E., Andrews, D. W., Glass, J., Curran, W. J., Glass, C., Champ, C. E., Evans, J. J., Hyslop, T., Pequignot, E. C., Downes, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.6941 · Cited by 345 · see citing works

Carcinomatous meningitis: Leptomeningeal metastases in solid tumors

Chamberlain, M. C., Rhun, É. L., & Taillibert, S. (2013) · Surgical Neurology International · doi:10.4103/2152-7806.111304 · Cited by 340 · see citing works

Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study

van den Bent, M. J., Tesileanu, C. M. S., Wick, W., Sanson, M., Brandes, A. A., Clément, P. M., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Baurain, J. F., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00090-5 · Cited by 332 · see citing works

Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial

Yamanaka, R., Homma, J., Yajima, N., Tsuchiya, N., Sano, M., Kobayashi, T., Yoshida, S., Abe, T., Narita, M., Takahashi, M., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0120 · Cited by 325 · see citing works

Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid Tumors

Krop, I. E., Demuth, T., Guthrie, T., Wen, P. Y., Mason, W. P., Chinnaiyan, P., Butowski, N. A., Groves, M. D., Kesari, S., Freedman, S. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.1540 · Cited by 321 · see citing works

Response Assessment Challenges in Clinical Trials of Gliomas

Wen, P. Y., Norden, A. D., Drappatz, J., & Lee, E. Q. (2010) · Current Oncology Reports · doi:10.1007/s11912-009-0078-3 · Cited by 39 · see citing works

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J. F., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,814 · see citing works

Quality of Treatment Response and Survival in Patients with Supra-Tentorial Malignant Gliomas

Maire, J.-P., Guerin, J. B., Dautheribes, M., Demeaux, H., Guichard, F., & Caudry, M. (1987) · Springer eBooks · doi:10.1007/978-94-009-3347-7_58

Response criteria for glioma

Sorensen, A. G., Batchelor, T. T., Wen, P. Y., Zhang, W., & Jain, R. K. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1204 · Cited by 191 · see citing works

Chemotherapy response criteria in malignant glioma

Grant, R., Liang, B. C., Slattery, J. M. A., Greenberg, H. S., & Junck, L. (1997) · Neurology · doi:10.1212/wnl.48.5.1336 · Cited by 67 · see citing works